The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, ...

Defactinib is an oral, selective inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the focal adhesion kinase family of non-receptor protein ...

Primary antibodies were used at a 1:200 dilution: p-Y-576/p-Y-577–FAK (focal adhesion kinase) (Cell Signaling, Boston, MA); FAK, actin, PECAM-1, β-catenin (Santa Cruz, Santa Cruz, CA ...

Defactinib is an oral, selective inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the focal adhesion kinase family of non-receptor protein ...

For the study, the researchers first looked for mRNAs at the feet, which are also known as focal adhesions. Previous research had identified a handful of mRNAs that localized around focal adhesions.

For the study, the researchers first looked for mRNAs at the feet, which are also known as focal adhesions. Previous research had identified a handful of mRNAs that localized around focal adhesions.

The secret to robust and reversible underwater adhesion: The answer lies in epidermal growth factor (EGF) domain Date: January 23, 2025 Source: Pohang University of Science & Technology (POSTECH ...

A research team at POSTECH has uncovered the molecular mechanism behind the remarkable underwater adhesion of hairy mussels (Barbatia virescens). Their findings, published in Nature Communications ...